Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HF 0220

Drug Profile

HF 0220

Alternative Names: 7β-hydroxy-epiandrosterone; 7β-OH-EPIA; HF0220

Latest Information Update: 24 Jul 2015

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hunter-Fleming
  • Developer Hunter-Fleming; Newron Pharmaceuticals
  • Class 17 ketosteroids; Androstanols; Neuroprotectants; Testosterone congeners
  • Mechanism of Action Antioxidants; Glucocorticoid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alzheimer's disease; Inflammatory bowel diseases; Psoriasis; Rheumatoid arthritis

Most Recent Events

  • 14 Sep 2010 HF 0220 is available for licensing worldwide as of 10 Sep 2010. http:///www.newron.com
  • 23 Oct 2008 Adverse events data from a phase II trial in Alzheimer's disease released by Hunter-Fleming
  • 31 Aug 2008 Hunter-Fleming completes a phase II trial in Alzheimer's disease in India, Sweden and the UK
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top